Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation
A single figure can sway a submission or a clinical decision. When continuous data are grouped with unequal intervals, a simple count by bin exaggerates wide ranges and hides concentrated patterns. Th
By Priya Raghavan, Biotech & Markets Analyst
Huntington's disease remains without a cure in 2025. Clinical practice focuses on symptom control while a new wave of molecular programmes seeks to slow or halt neurodegeneration. The evidence base po
By Dr. Eleanor Vance, Regulatory Affairs Editor
A familiar antibiotic has crossed an ocean with an unfamiliar name. In April 2024 the U.S. Food and Drug Administration approved Pivya pivmecillinam for uncomplicated urinary tract infection in adult
By Dr. Eleanor Vance, Regulatory Affairs Editor
Testosterone replacement therapy is widely requested, yet appropriate use depends on accurate diagnosis. True androgen deficiency is a clinical and biochemical syndrome. Symptoms must align with repea
By Tom Okafor, Clinical Trials Correspondent
Five years after the acute waves of COVID-19, Long COVID has settled into public health planning as a common post-infectious condition with sustained clinical, economic and social effects. The term de
By Dr. Eleanor Vance, Regulatory Affairs Editor
Nitazenes are highly potent synthetic opioids from the benzimidazole family that now present a fast-moving threat in the United Kingdom and in other regions. The core scaffold places them apart from n
By Dr. Eleanor Vance, Regulatory Affairs Editor
Public attention to nicotinamide mononucleotide has grown quickly as evidence about NAD+ biology has entered mainstream discussion. Early animal data suggested broad benefits across metabolic and vasc
By Dr. Eleanor Vance, Regulatory Affairs Editor
Cellular ageing is not a single event but a convergence of gradual molecular failures that accumulate over time. The recognised hallmarks include telomere attrition, genomic instability from DNA damag
By Dr. Eleanor Vance, Regulatory Affairs Editor
Molecular biology studies how DNA, RNA and proteins control the behaviour of cells. It asks how genetic information is stored, copied, transcribed and translated, then traces how those molecular instr
By Dr. Eleanor Vance, Regulatory Affairs Editor
Exposure and Response Prevention (ERP) sits at the centre of modern, evidence-based care for obsessive and anxiety-driven conditions. It is a structured behavioural method that asks people to face wha
By Tom Okafor, Clinical Trials Correspondent
The idea that a single infusion of a patient's own immune cells could clear aggressive cancer once seemed like daring fiction. CAR T‑cell therapy has turned that notion into clinical fact, standing sh
By Dr. Eleanor Vance, Regulatory Affairs Editor
The hot flush that wakes you at 03:00, the sudden fog that steals a board‑room sentence, the invisible shift that hollows bones – the menopausal transition is blunt. Yet for many, relief sits in plain
By Dr. Eleanor Vance, Regulatory Affairs Editor
Subscribe to our weekly pharmaceutical intelligence digest
We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy